Items Tagged ‘Non-Hodgkin’s Lymphoma’

February 10, 2012

Two Different Approaches to Rituxan Both Effective For Follicular Lymphoma

By

Among patients with low-tumor-burden follicular lymphoma who have received initial treatment with Rituxan® (rituximab), waiting until disease progression to take additional Rituxan is as effective as ongoing, maintenance Rituxan. These results were presented at the 53rd Annual meeting of the American Society of Hematology. Follicular lymphoma is an indolent (slow-growing) type of non-Hodgkin’s lymphoma. It […]

View full entry

Tags: Indolent/Low Grade Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma


April 19, 2011

Additional Rare Cancer Cases Reported Among Users of TNF Blockers

By

The US Food and Drug Administration (FDA) has received additional reports of a rare type of cancer—hepatosplenic T-cell lymphoma—primarily among adolescents and young adults who are being treated for Crohn’s disease or ulcerative colitis with medications known as tumor necrosis factor (TNF) blockers as well as azathioprine and/or mercaptopurine. TNF blockers include Remicade® (infliximab), Enbrel® […]

View full entry

Tags: Health and Wellness, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


March 31, 2009

Maintenance Rituxan® Prolongs Survival in Advanced Indolent Lymphoma

By

Maintenance Rituxan® (rituximab) given after standard chemotherapy significantly prolongs progression-free survival (PFS) in patients with advanced-stage indolent non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.1  Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. It is characterized by excessive accumulation […]

View full entry

Tags: Non-Hodgkin's Lymphoma


February 6, 2009

Understanding Targeted Therapy for Non-Hodgkin’s Lymphoma

By

Targeted therapies are anticancer drugs that are designed to treat cancer cells while minimizing damage to normal, healthy cells. These drugs, which may be used in the treatment of non-Hodgkin’s lymphoma, interfere with specific pathways involved in cancer cell growth or survival. Some targeted therapies block growth signals from reaching cancer cells; others reduce the […]

View full entry

Tags: Non-Hodgkin's Lymphoma


February 6, 2009

Lymphoma Patients: Understanding Peripheral Neuropathy

By

If you’ve received chemotherapy as part of your lymphoma treatment, one of the side effects you may experience is numbness and tingling in you extremities, also known as peripheral neuropathy. The following guidelines explain how to recognize and manage this condition. What Is Peripheral Neuropathy? Numbness and tingling of your extremities (hands and feet) is […]

View full entry

Tags: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma


February 6, 2009

It's Not Just a Little Fever: Preventing Infection during Therapy for Lymphoma

By

Many cancer patients are at an increased risk of infection because of their low levels of infection-fighting white blood cells, a condition called neutropenia. The most common reason that cancer patients experience neutropenia is as a side effect of chemotherapy. Chemotherapy involves the use of drugs to destroy cancer cells. Chemotherapy works by destroying cells […]

View full entry

Tags: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma


February 6, 2009

Successful Treatment for Lymphoma Means Staying on Schedule

By

In order to receive the best possible benefit from your lymphoma therapy, it is important to follow your treatment as your doctor has prescribed. Even if you’re not able to visit your regular treatment facility, chances are good that you can still maintain your schedule; many other doctors, nurses, and healthcare providers are able to […]

View full entry

Tags: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma


February 5, 2009

Understanding Dose-dense Therapy for Non-Hodgkin’s Lymphoma and Breast Cancer

By

Dose-dense chemotherapy is a treatment approach where chemotherapy is administered as frequently as possible with the goal of delivering the greatest amount of chemotherapy over the shortest period of time, thereby delivering the maximum amount of chemotherapy drug to the cancer. Increasing the dose and frequency of chemotherapy administration appears to increase survival in some […]

View full entry

Tags: Breast Cancer, Non-Hodgkin's Lymphoma